Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients

European Neuropsychopharmacology

Volumn 22, Issue 10, 2012, Pages 695-703

  Wang, Sheng Chang ^a   Tsou, Hsiao Hui ^a   Chen, Chia Hui ^a   Chen, Yu Ting ^a   Ho, Ing Kang ^a,b,c   Hsiao, Chin Fu ^a,b   Chou, Sun Yuan ^d   Lin, Yen Feng ^e   Fang, Kai Chi ^f   Huang, Chieh Liang ^b   Su, Lien Wen ^g   Fang, Yung Chun ^g   Liu, Ming Lun ^h   Wu, Hsiao Yu ^a   Lin, Keh Ming ^a   Liu, Shu Chih ^a   Kuo, Hsiang Wei ^a   Chiang, I Chen ^c   Chen, Andrew C H ⁱ   Tian, Jia Ni ^a   Liu, Yu Li ^a,c,j   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Taoyuan Mental Hospital   (Taiwan)

^e EN CHU KONG HOSPITAL   (Taiwan)

^f FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^g TAIPEI CITY HOSPITAL   (Taiwan)

^h Wei Gong Memorial Hospital   (Taiwan)

ⁱ Wei Gong Memorial Hospital ^*  (United States)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Change in libido; Insomnia; Methadone; OPRM1; TESS

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; BENZODIAZEPINE DERIVATIVE; GENOMIC DNA; HYPNOTIC AGENT; METHADONE; MU OPIATE RECEPTOR;

ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BONE PAIN; CLINICAL OPIOID WITHDRAWAL SCALE; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; EPIPHORA; FATIGUE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HEROIN DEPENDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; METHADONE TREATMENT; MU1 OPIOID RECEPTOR GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PULSE RATE; PUPIL; RATING SCALE; RECEPTOR GENE; RESTLESSNESS; RHINORRHEA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TREATMENT EMERGENT SYMPTOMS SCALE; TREATMENT RESPONSE; TREMOR; URINALYSIS; URINE MORPHINE TEST; WITHDRAWAL SYNDROME; YAWNING;

ADULT; ANALGESICS, OPIOID; BENZODIAZEPINES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HEROIN DEPENDENCE; HUMANS; HYPNOTICS AND SEDATIVES; LIBIDO; MALE; METHADONE; MORPHINE; OPIATE SUBSTITUTION TREATMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; TAIWAN;

EID: 84865565339     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.002     Document Type: Article

References (47)

1. Athanasos P., Smith C.S., White J.M., Somogyi A.A., Bochner F., Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 2006, 120:267-275.
2. Barrett J., Fry B., Maller J., Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Bart G., Kreek M.J., Ott J., LaForge K.S., Proudnikov D., Pollak L., Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
4. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9608-9613.
5. Bunten H., Liang W.J., Pounder D.J., Seneviratne C., Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin. Pharmacol. Ther. 2010, 88:383-389.
6. Bunten H., Liang W.J., Pounder D., Seneviratne C., Osselton M.D. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict. Biol. 2011, 16:142-144.
7. Compton P., Geschwind D.H., Alarcon M. Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am. J. Med. Genet. B. 2003, 121B:76-82.
8. Crettol S., Besson J., Croquette-Krokar M., Hammig R., Gothuey I., Monnat M., Deglon J.J., Preisig M., Eap C.B. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1722-1727.
9. Crystal H.A., Hamon S., Randesi M., Cook J., Anastos K., Lazar J., Liu C., Pearce L., Golub E., Valcour V., Weber K.M., Holman S., Ho A., Kreek M.J. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict. Biol. 2012, 17:181-191.
10. Deb I., Chakraborty J., Gangopadhyay P.K., Choudhury S.R., Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 2010, 112:486-496.
11. Donny E.C., Brasser S.M., Bigelow G.E., Stitzer M.L., Walsh S.L. Methadone doses of 100mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005, 100:1496-1509.
12. Fillingim R.B., Kaplan L., Staud R., Ness T.J., Glover T.L., Campbell C.M., Mogil J.S., Wallace M.R. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain 2005, 6:159-167.
13. Fonseca F., Gratacos M., Escaramis G., De Cid R., Martin-Santos R., Fernandez-Espejo E., Estivill X., Torrens M. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol. Diagn. Ther. 2010, 14:171-178.
14. Franke P., Wang T., Nothen M.M., Knapp M., Neidt H., Albrecht S., Jahnes E., Propping P., Maier W. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am. J. Med. Genet. 2001, 105:114-119.
15. Hanbury R., Cohen M., Stimmel B. Adequacy of sexual performance in men maintained on methadone. Am. J. Drug Alcohol Abuse 1977, 4:13-20.
16. Hartel D.M., Schoenbaum E.E., Selwyn P.A., Kline J., Davenny K., Klein R.S., Friedland G.H. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am. J. Public Health 1995, 85:83-88.
17. Hayashida M., Nagashima M., Satoh Y., Katoh R., Tagami M., Ide S., Kasai S., Nishizawa D., Ogai Y., Hasegawa J., Komatsu H., Sora I., Fukuda K., Koga H., Hanaoka K., Ikeda K. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008, 9:1605-1616.
18. Johnson S.M., Kinney M.E., Wiegel L.M. Inhibitory and excitatory effects of micro-, delta-, and kappa-opioid receptor activation on breathing in awake turtles, Trachemys scripta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1599-R1612.
19. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., Skorpen F. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 2004, 48:1232-1239.
20. Kreek M.J. Opiates, opioids and addiction. Mol. Psychiatry 1996, 1:232-254.
21. Kurth M.E., Sharkey K.M., Millman R.P., Corso R.P., Stein M.D. Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordings. J. Addict. Dis. 2009, 28:219-225.
22. Lotsch J., Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?. Trends Mol. Med. 2005, 11:82-89.
23. Lotsch J., Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006, 6:200-210.
24. Marsden J., Farrell M., Bradbury C., Dale-Perera A., Eastwood B., Roxburgh M., Taylor S. Development of the treatment outcomes profile. Addiction 2008, 103:1450-1460.
25. Martin T., Kahn W., Xiao R., Childers S. Differential regional effects of methadone maintenance compared to heroin dependence on £g-opioid receptor desensitization in rat brain. Synapse 2007, 61:176-184.
26. Mattick R., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, 3:1-34.
27. Narita M., Funada M., Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol. Ther. 2001, 89:1-15.
28. Nishizawa D., Han W., Hasegawa J., Ishida T., Numata Y., Sato T., Kawai A., Ikeda K. Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 2006, 53:137-141.
29. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., Schmidt P.H., Lotsch J. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 2009, 284:6530-6535.
30. Oroszi G., Anton R.F., O'Malley S., Swift R., Pettinati H., Couper D., Yuan Q., Goldman D. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcoholism (NY) 2009, 33:383-393.
31. Pan Y.X., Xu J., Xu M., Rossi G.C., Matulonis J.E., Pasternak G.W. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4917-4922.
32. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., Lynch K.G., O'Malley S., Berrettini W.H., Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology 2006, 188:355-363.
33. Rodi C., Darnhofer-Patel B., Stanssens P., Zabeau M., van den Boom D. A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques 2002, 32:S62-S69.
34. Roy S., Liu H.C., Loh H.H. mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. Mol. Brain Res. 1998, 56:281-283.
35. Shabalina S.A., Zaykin D.V., Gris P., Ogurtsov A.Y., Gauthier J., Shibata K., Tchivileva I.E., Belfer I., Mishra B., Kiselycznyk C., Wallace M.R., Staud R., Spiridonov N.A., Max M.B., Goldman D., Fillingim R.B., Maixner W., Diatchenko L. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 2009, 18:1037-1051.
36. Sharkey K.M., Kurth M.E., Anderson B.J., Corso R.P., Millman R.P., Stein M.D. Assessing sleep in opioid dependence: a comparison of subjective ratings, sleep diaries, and home polysomnography in methadone maintenance patients. Drug Alcohol Depend. 2011, 113:245-248.
37. Shi J., Hui L., Xu Y., Wang F., Huang W., Hu G. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum. Mutat. 2002, 19:459-460.
38. Storey J. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Stat. 2003, 31:2013-2035.
39. Tost J., Gut I.G. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 2005, 38:335-350.
40. Trksak G.H., Jensen J.E., Plante D.T., Penetar D.M., Tartarini W.L., Maywalt M.A., Brendel M., Dorsey C.M., Renshaw P.F., Lukas S.E. Effects of sleep deprivation on sleep homeostasis and restoration during methadone-maintenance: a [31]P MRS brain imaging study. Drug Alcohol Depend. 2010, 106:79-91.
41. Walter C., Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009, 146:270-275.
42. Wang S.C., Ho I.K., Wu S.L., Liu S.C., Kuo H.W., Lin K.M., Liu Y.L. Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. Biomed. Chromatogr. 2010, 24:782-788.
43. Way B.M., Taylor S.E., Eisenberger N.I. Variation in the mu-opioidreceptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15079-15084.
44. Wesson D.R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). J. Psychoactive Drugs 2003, 35:253-259.
45. Wolff K., Sanderson M., Hay A.W., Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin. Chem. 1991, 37:205-209.
46. Xin L., Wang Z.J. Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants. AAPS PharmSci 2002, 4:E23.
47. Yuan H.Y., Chiou J.J., Tseng W.H., Liu C.H., Liu C.K., Lin Y.J., Wang H.H., Yao A., Chen Y.T., Hsu C.N. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006, 34:W635-W641.